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The fruit hull of Gleditsia sinensis (FGS) has been prescribed as a traditional eastern Asian medicinal remedy for the treatment
of various respiratory diseases, but the eﬃcacy and underlying mechanisms remain poorly characterized. Here, we explored
a potential usage of FGS for the treatment of acute lung injury (ALI), a highly fatal inﬂammatory lung disease that urgently
needs eﬀective therapeutics, and investigated a mechanism for the anti-inﬂammatory activity of FGS. Pretreatment of C57BL/6
mice with FGS signiﬁcantly attenuated LPS-induced neutrophilic lung inﬂammation compared to sham-treated, inﬂamed mice.
Reporter assays, semiquantitative RT-PCR, and Western blot analyses show that while not aﬀecting NF-κB, FGS activated Nrf2
and expressed Nrf2-regulated genes including GCLC, NQO-1, and HO-1 in RAW 264.7 cells. Furthermore, pretreatment of mice
with FGS enhanced the expression of GCLC and HO-1 but suppressed that of proinﬂammatory cytokines in including TNF-α and
IL-1β in the inﬂamed lungs. These results suggest that FGS eﬀectively suppresses neutrophilic lung inﬂammation, which can be
associated with, at least in part, FGS-activating anti-inﬂammatory factor Nrf2. Our results suggest that FGS can be developed as a
therapeutic option for the treatment of ALI.
1.Introduction
Acute lung injury (ALI) and acute respiratory distress syn-
drome (ARDS) are severe inﬂammatory diseases character-
ized by cellular and tissue injury, lung compliance abnor-
mality, and gas change impairment, which frequently lead
to fatal respiratory failure within hours [1, 2]. Pulmonary
or extrapulmonary insults, such as pneumonia, aspiration,
trauma, and sepsis, cause ALI/ARDS [3], and sepsis is the
most common initiator of ALI/ARDS [4]. In bacterial sepsis,
lipopolysaccharide (LPS), a major component of Gram-neg-
ative bacterial cell wall, plays a key role in inducing in-
ﬂammation because it stimulates the production of proin-
ﬂammatory cytokines including interleukin (IL)-8, causing2 Evidence-Based Complementary and Alternative Medicine
the inﬁltration of neutrophils into the lungs of ALI patients
[5,6].Therefore,suppressingLPS-inducedinﬂammationhas
been a primary target in pharmacologic treatment of ALI/
ARDS patients.
LPS binds to its receptor, Toll-like receptor 4 (TLR4), to
activate a key proinﬂammatory transcription factor NF-κB
that induces expressions of various proinﬂammatory cytoki-
nes and chemokines such as TNF-α,I L - 1 β,a n dM I P - 1 α [7].
On the premise that blocking NF-κB activity and produc-
tion of proinﬂammatory cytokines suppresses inﬂammation,
numerous clinical trials have been carried out, but shown
no signiﬁcant eﬀect on ALI/ARDS. Current pharmacological
therapies for ALI/ARDS include inhalation of nitric oxide
(NO) to relieve pulmonary hypertension and administration
of corticosteroids for ARDS-related pulmonary ﬁbrosis [8,
9]. These treatments, however, lack ﬁrm support by clinical
evidence and show severe adverse eﬀects such as toxicity
caused by reactive free radicals generated from NO and
prolonged neuromuscular weakness, deregulation of glucose
metabolism, and sepsis caused by systemic corticosteroid ad-
ministration [1, 10]. Given that the only proven treatment
to improve survival is mechanical ventilation with a lung
protective strategy [11], it is imperative to develop eﬀective
therapeutics for ALI/ARDS.
In traditional eastern Asian medicine, the fruit hull of
Gleditsia sinensis (FGS) LAM (Leguminosae) has long been
used to treat various respiratory symptoms such as dyspnea,
orthopnea, cough with phlegm, and sore throat. In addition,
it has been administered externally for the treatment of sub-
cutaneous pyogenic infections [12]. Therefore, we postulate
that the therapeutic eﬀect of FGS is attributed to a potent
anti-inﬂammatory activity in its constituents. In this study,
we tested this possibility by using ALI/ARDS animal model.
Since the underlying mechanisms for the eﬃcacy of the
remedy are largely unknown, we investigated possible mech-
anisms by which FGS suppresses inﬂammation by using
macrophagecelllines.OurresultsshowthatFGSiscapableof
suppressing neutrophilic lung inﬂammation in LPS-induced
ALI mouse model, which is associated with, at least in
part, activation of NF-E2-related factor 2 (Nrf2), an anti-
inﬂammatory transcription factor that plays a key role in
ameliorating acute lung injury [13].
2.MaterialandMethods
2.1. Preparation of the Water Extract of G. sinensis Fruit
Hull. The fruits of G. sinensis were purchased from Kwang-
Myoung-Dang herb store (Pusan, Republic of Korea) and
authenticatedbyProfessorC.W.HanattheSchoolofKorean
Medicine, Pusan National University, Yangsan, Republic of
Korea. A voucher specimen (number: pnukh001) is kept in
the School of Korean Medicine, Pusan National University. A
decoction was obtained by boiling 300g of the fruit hulls of
G. sinensis in distilled water for 2 hours followed by ﬁltration
through 0.45μm ﬁlter. The resultant decoction underwent
a freeze-drying process to yield 60g of powder. Appropriate
amountofthepowderwasdissolvedintophosphate-buﬀered
saline (PBS) prior to experiment.
2.2. Reagents and Antibodies. 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide(MTT),Sulforaphane,and
Gram-negative Escherichia coli LPS (serotype 055:B5) for
animal study were purchased from Sigma Chemical Co. (St.
Louis, MO, USA). TLR4-speciﬁc E. coli LPS was purchased
from Alexis Biochemical (San Diego, CA, USA). All antibod-
ies used in this study were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA).
2.3. Animals and ALI/ARDS Model. Male C57BL/6 mice, in-
bred in a speciﬁc pathogen-free (SPF) facility, were pur-
chased from the Samtaco Bio Korea, Ltd. (Osan, Korea).
Animals were housed in certiﬁed, standard laboratory cages,
and fed with food and water ad libitum prior to experiment.
All experimental procedures followed the Guidelines for the
Care and Use of Laboratory Animals of the NIH of Korea,
and all the experiments were approved by the Institutional
Animal Care and Use Committee of Pusan National Univer-
sity, Pusan, Republic of Korea.
Prior to LPS administration, mice were fed once with
either 3.3 or 13.3mg of FGS per kilogram of a mouse for
14 days, the amount of which was same as, or 4 times high-
er, respectively, than that of FGS prescribed to patients in
Korean medicine clinic. A single dose of FGS was in 250μL
of ddH2O, and feeding did not cause any adverse eﬀect on
mice. At day 15, mice were anesthetized by Zoletil (Virbac)
and received a single dose of 10mg LPS/kg body weight
intranasally while control mice received sterile saline. At 24h
after the administration of LPS, mice were euthanized by
CO2 gas. The trachea was exposed through midline incision
andcannulatedwithasterile24-gaugeintravascularcatheter.
Bilateral bronchoalveolar lavage (BAL) was performed by
two consecutive instillations of 1.0mL of PBS. Total cell
numbers in BAL ﬂuid were counted with hemocytometer.
Then, the cells in BAL ﬂuid were precipitated by a cytospin
and stained for macrophages, lymphocytes, or neutrophils
with Hemacolor (Merck, Darmstadt, Germany). Three hun-
dred cells in total were counted, and one hundred cells in
each microscopic ﬁeld were scored. The mean numbers of
the cells per ﬁeld are shown.
For the analysis of lung tissue, mice were perfused with
saline and the whole lung was inﬂated with ﬁxatives. After
paraﬃn embedding, 5μm sections were cut and placed
on charged slides and stained with hematoxylin and eosin
(H&E) staining method. Three separate H&E-stained sec-
tions were evaluated in 200x microscopic magniﬁcations per
mouse.
2.4. Cell Culture. RAW 264.7 cells (American Type Culture
Collection, Rockville, MD, USA) were culturedin Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) containing L-glutamine
(200mg/L) (Invitrogen; Carlsbad, CA, USA) supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS)
and100U/mLpenicillinand100μg/mLstreptomycin(Invit-
rogen) and maintained in a humidiﬁed incubator at 37◦C
and 5% CO2 prior to experiment.
2.5. Microculture Tetrazolium (MTT) Assay. The cytotoxicity
caused by FGS was assessed with MTT-based colorimetricEvidence-Based Complementary and Alternative Medicine 3
assay (Skehan, 1998). In brief, after Griess reaction, MTT
solution(2.0mg/mL)wasaddedtoeachwellofcellscultured
in a 96-well plate. At 4h after incubation at 37◦Ci naC O 2
cell culture incubator, the supernatants were removed, and
formazan crystals formed in viable cells were measured at
540nm with a microplate reader. The percentage of living
cells was calculated against untreated cells.
2.6. Western Blot Analysis. Total cell extract of 5 × 106 cells
was prepared as described previously [14]. Nuclear proteins
were isolated by NE-PER nuclear extraction kit and the
manufacture’s protocol (Thermo Scientiﬁc, IL, USA). The
amounts of proteins were measured by Bradford (Bio-Rad
Laboratories, Hercules, CA, USA). Equal amounts of pro-
teins were fractionated by SDS-PAGE and then transferred
to PVDF membrane (Bio-Rad Laboratories). Blots were
blocked for at least 1h with 5% nonfat dry milk prior to
incubation with Nrf2, NF-κB (p65), lamin A/C polyclonal
antibodies at 4◦C for overnight. After incubation with sec-
ondary antibodies conjugated with HRP for 1h at room
temperature, the bands of interest were revealed by chemi-
luminescence (SuperSignal West Femto, Thermo Scientiﬁc).
2.7. Measurement of Nitric Oxide (NO) Production. RAW
264.7 cells were treated with 2.5 or 5μg/mL of FGS for
16h prior to LPS (100ng/mL) treatment for 16h. Produced
NO was determined by measuring the stable conversion
product of NO, nitrite (NO2
−). Brieﬂy, 100 μLo fc e l lc u l t u r e
medium was mixed with 100μL of Griess reagent (0.1%
N-(1)-naphthyl-ethylenediamine, 1.0% sulfanilamide, and
2.5% phosphoric acid) in a 96-well plate and incubated at
room temperature for 5min prior to reading at 540nm with
a microplate reader. Sodium nitrite (NaNO2)w a su s e df o r
setting up a standard curve.
2.8. Reporter Constructs, Reporter Cell Line, and Luciferase
Assay. For the measurement of Nrf2 transcriptional activity,
an Nrf2 reporter cell line was created. From genomic
DNA isolated by QIAmp DNA Mini Kit (Qiagen) and
the instructions of the manufacture, the proximal 1kb-
long promoter of a murine NQO-1 gene, where an Nrf2
binding site locates, was ampliﬁed by PCR with a pair
of primers: 5 -GCTATGTGGACCAGTCTGG-3  and 5 -
GGCTCCAGATGTTGAGGGA-3 . The PCR product was
veriﬁedbysequencingandsubsequentlyclonedintopGL4.17
[luc2/Neo] vector (Promega). The resultant vector, NQO-
1[luc/Neo], was stably transfected into RAW 264.7 cells,
and candidate Nrf2 reporter cell lines were selected under
G418 (Invitrogen). The Nrf2 reporter cell line was tested for
its responsiveness to Sulforaphane, a well-documented Nrf2
activator. Luciferase activity was measured by a luciferase
assaykit (Promega)and the instructions of the manufacturer
and normalized by the amount of total proteins of the cell
extract.
2.9. Isolation of Total RNA from Cells and RT-PCR. Total
RNA of tissue and cells was isolated with the QIAGEN
RNeasyminikit (Qiagen,Hilden,Germany)accordingtothe
manufacturer’s instructions. Three micrograms of total RNA
were reverse-transcribed by M-MLV reverse transcriptase
(Promega, Madison, WI, USA), and single-stranded cDNA
wasampliﬁedbyPCRwithasetofspeciﬁcprimersasfollows:
the forward and the reverse primers for NQO-1 were 5 -
GCAGTGCTTTCCATCACCAC-3  and 5 -TGGAGTGTG-
CCCAATGCTAT-3 , respectively; the primers for HO-1
were 5 -TGAAGGAGGCCACCAAGGAGG-3  and 5 -AGA-
GGTCACCCAGGTAGCGGG-3 , respectively; the primers
for GCLC were 5 -CACT GCCAGAACACAGACCC-3  and
5 -ATGGTCTGGCTGAGAAGCCT-3 , respectively; the
primers for TNF-α were 5 -CTACTCCTCAGAGCCCCC-
AG-3  and 5 -AGGCAACCTGACCACTCTCC-3 ,r e s p e c -
tively; the primers for IL-1β were 5 -GTGTCTTTCCCG-
TGGACCTT-3  and 5 -TCGTTGCTTGGTTCTCCTTG-3 ,
respectively; the primers for GAPDH were 5 -GGAGCC-
AAAAGGGTCATCAT-3  and 5 -GTGATGGCATGGACT-
GTGGT-3 , respectively. For PCR ampliﬁcation, TaqPCRx
DNA polymerase, Recombinant (Invitrogen, Carlsbad, CA,
USA), and the manufacturer’s protocol were used. The reac-
tion conditions were as follows: an initial denaturation at
95◦C for 5min followed by 22–30 cycles of denaturation for
40sec at 95◦C, annealing for 40sec at 57◦C, and extension
for 50sec at 72◦C with a ﬁnal extension for 7min at 72◦C.
Amplicons were separated in 1.2% agarose gels in 1× TBE
buﬀer at 100V for 30min, stained with ethidium bromide,
and visualized under UV light. GAPDH (Glyceraldehyde-3-
phosphate dehydrogenase) was used as internal controls to
evaluate relative expressions of NQO-1, GCLC, and HO-1.
Relative expression of each gene over GAPDH was deter-
mined by densitometric analysis software ImageJ (Wayne
Rasband, Research Services Branch, National Institute of
Mental Health, Bethesda, Maryland, USA).
2.10. Measurement of Reactive Oxygen Species (ROS) Pro-
duction. Intracellular ROS generation in RAW 264.7 cells
was determined by carboxy-H2DCFDA (5-(and-6)-car-
boxy-2 ,7 -dichlorodihydroﬂuorescein diacetate (Molecular
Probes, Eugene, OR, USA). Brieﬂy, after various pharmaco-
logicaltreatments,RAW264.7cellsweretreatedwith100μM
carboxy-H2DCFDA in cultured medium and incubated at
37◦C for 30min. After incubation, the cells were washed
with PBS and then ﬂuorescence was measured by using BD
FACS Canto II (BD Biosciences, San Jose, CA, USA) at an
excitation wavelength of 488nm and an emission wavelength
of 525nm.
2.11. Statistical Analysis. For comparison among groups,
one-way analysis of variance (ANOVA) tests with Tukey’s
post hoc test was used (with the assistance of InStat, Graph-
pad Software, Inc., San Diego, CA) (P values <0.05 are con-
sidered signiﬁcant). All the experiment was performed at
least three times independently.
3. Results
3.1. The Water Extract of FGS Suppresses Acute Neutrophilic
Lung Inﬂammation in an ALI/ARDS Mouse Model. Since the4 Evidence-Based Complementary and Alternative Medicine
ddH2O + sham
100 μm
(a)
FGS (13.3 mg/kg) + sham
100 μm
(b)
ddH2O + LPS
100 μm
(c)
FGS (3.3 mg/kg) + LPS
100 μm
(d)
FGS (13.3 mg/kg) + LPS
100 μm
(e)
0
50
100
150
200
250
300
W
a
t
e
r
 
+
 
P
B
S
F
G
S
-
h
 
+
 
P
B
S
W
a
t
e
r
 
+
 
L
P
S
F
G
S
-
l
 
+
 
L
P
S
F
G
S
-
h
 
+
 
L
P
S
N
u
m
b
e
r
 
o
f
 
c
e
l
l
s
 
(
×
1
0
3
c
e
l
l
s
/
m
L
)
Total cells
Macrophage
Neutrophil
Lymphocyte
∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗
(f)
Figure 1: FGS suppresses acute neutrophilic lung inﬂammation in an ALI animal model. (a)–(e) H&E-stained lung sections of C57BL/6
mice. C57BL/6 mice, fed with either water (a) and (c) or FGS (b), (d), and (e) for 14 days, received an intranasal LPS (c), (d), and (e) or
PBS (a) and (b) (n = 5 per group). At 24h after LPS treatment, the lungs of mice were perfused and analyzed by histological examination
(magniﬁcation × 200). LPS treatment shows signiﬁcant cellular inﬁltrates (c), which are decreased by FGS treatments (d) and (e). Shown
are representatives of at least ﬁve diﬀerent areas of a lung. (f) Bronchoalveolar lavage (BAL) was performed to count inﬁltrates in the lung.
Total cell numbers were counted by using a hemocytometer. The cells in BAL ﬂuid were precipitated by a cytospin and diﬀerentially counted
for macrophages, neutrophils, and other inﬂammatory cells. Data represent the mean ± SEM of three independent counting. ∗P<0.05,
∗∗∗P<0.001; signiﬁcantly diﬀerent from group C by post ANOVA comparison with Tukey’s post hoc test.Evidence-Based Complementary and Alternative Medicine 5
aqueous extract of the fruit hull of G. sinensis (FGS) LAM
has been prescribed to treat various respiratory diseases, we
hypothesized that FGS is eﬀective in treating inﬂammatory
lung diseases by suppressing inﬂammation. To test our
hypothesis, we used an ALI/ARDS mouse model, one of the
hallmarks of which is neutrophilic lung inﬂammation. The
water extract of FGS was prepared and administered orally
to seven-week old C57BL/6 mice for 14 days. Mice received
either 3.3mg/kg of FGS (n = 10), equivalent to the dose
administered to a patient per day, or 13.3mg/kg of FGS
(n = 10), 4 times higher than the dose for a patient. At
day 15, mice were divided half, and one half received sham
treatment, and the other half did an intranasal instillation of
LPS (10mg/kg) to induce acute lung inﬂammation. At 24h
after LPS administration, the mice were euthanized for the
analysis of lung inﬂammation. Histological analyses of lung
sections show that the mice received FGS and sham treat-
ments kept the lung structure intact, similar to control mice
treatedwithwaterandsham(Figures1(a)and1(b)),suggest-
ing that FGS treatment did not provoke any inﬂammation.
The lungs of mice received an intranasal LPS developed
severe lung inﬂammation, as evidenced by the edematous
alveolarwallthickenedwithsevereinﬂammatorycellinﬁltra-
tion(Figure 1(c)).However,thedegreeoflunginﬂammation
was signiﬁcantly reduced by FGS treatments (Figures 1(d)
and 1(e)). It is notable that the higher dose of FGS made the
inﬂamed lung return close to the control level (Figure 1(e)).
We also performed diﬀerential counting of inﬁltrates in
BALﬂuidobtainedfromvariouslytreatedmice,showingthat
thenumbersoftotalcellularinﬁltratesandneutrophilsinthe
lungs induced by LPS instillation were reduced by 53.2% and
62.8%, respectively, when the mice were treated with
3.3mg/kg of FGS (Figure 1(f)). Reduction of inﬂammatory
cellular inﬁltration was more evident when the mice were
treated with 13.3mg/kg of FGS: those of cellular inﬁltrates
andneutrophilsweredownby77.6%and84.4%,respectively
(compared the 3rd group of columns to the 5th group).
Together, these results demonstrate that FGS strongly sup-
presses acute neutrophilic lung inﬂammation.
3.2. FGS Did Not Aﬀect NF-κBA c t i v i t y .Since NF-κBi sa
well-documented transcription factor that regulates expres-
sions of numerous proinﬂammatory cytokines and NF-κB
activity was reported to increase in patients with acute lung
injury [15], we tested the possibility that FGS exerts its anti-
inﬂammatoryfunctionbysuppressingproinﬂammatoryNF-
κB activity. First, to determine an optimal dose of FGS
without signiﬁcant cellular toxicity, we performed MTT
assays with RAW 264.7 cells, a murine macrophage cell line.
The cells were treated with various amounts, from 10 to
100μg/mL, of FGS for 16h prior to MTT assay. As shown
in Figure 2, FGS did not show any signiﬁcant cellular toxicity
except100μg/mL,inwhichaslightcytotoxicitywasdetected.
Forthestudy,weusedleast,yeteﬀective,amountsofFGS,2.5
and 5μg/mL.
Next, we tested whether FGS aﬀects NF-κBa c t i vi ty .R A W
264.7 cells, pretreated with two diﬀerent amounts of FGS
(2.5μg/mL or 5μg/mL) for 16h, were treated with highly
puriﬁed, TLR4 speciﬁc LPS (100ng/mL) for 15 or 30min.
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Figure 2: Eﬀect of FGS on cell viability. Cytotoxic eﬀect of FGS
on RAW 264.7 cells was measured by MTT assay. The cells were
treated with various amounts of FGS for 16h prior to MTT assay.
Data represent the mean ± SEM of three independent determines.
∗∗∗P<0.001, which was signiﬁcantly diﬀerent compared to
control.
Nuclear proteins from the diﬀerentially treated cells were
prepared and analyzed by western blotting for nuclear p65,
a subunit of NF-κB. As shown in Figure 3(a), LPS treatments
induced nuclear localization of p65, indicative of NF-κB
activation (lanes 1, 4, and 7). However, pretreatment with
2.5μg/mL or 5μg/mL of FGS did not signiﬁcantly, albeit
m a r g i n a l l yb y5μg/mL of FGS, aﬀect the nuclear localization
of p65 (lanes 5–9 compared to lanes 4 and 7), suggesting that
FGS may not aﬀect NF-κBa c t i v i t y .
Since NF-κB plays a key role in regulating the expression
of proinﬂammatory cytokines such as TNF-α and IL-1β [7]
andinducingiNOSandtherebyproducingnitricoxide(NO)
in macrophages [16], we further tested whether or not FGS
aﬀects NF-κB activity by measuring LPS-induced TNF-α
and NO production in macrophages. RAW 264.7 cells were
pretreated with FGS and then treated with LPS (100ng/mL).
At 24h after the treatment, the levels of TNF-α (Figure 3(b))
and NO (Figure 3(c)) were determined by semiquantitative
RT-PCR and nitrite measurement, respectively. As shown in
Figure 3(b), LPS treatment induced the expression of TNF-
α (the 2th column), which was not signiﬁcantly aﬀected by
FGS treatments (3th, 4th, and 5th columns). In experiment
fortheeﬀectofFGSonIL-1β expression,weobtainedsimilar
results (data not shown). As shown in Figure 3(c),L P S
treatment induced the production of a signiﬁcant amount of
NO (the 4th column), which was not signiﬁcantly aﬀectedby
FGS treatments either (the 5th and 6th columns). Together,
theseresultssuggestthatFGSinourexperimentalconditions
does not aﬀect NF-κBa c t i v i t y .
3.3. FGS Activates Nrf2 and Induces the Expression of Nrf2-
Regulated Genes. Since our results show no signiﬁcant
involvement of FGS in NF-κB activity, we explored another
possibility that the anti-inﬂammatory function of FGS is
mediated by activating Nrf2, an anti-inﬂammatory tran-
scription factor that prevents from acute lung inﬂammation6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: FGS does not aﬀect NF-κB activity. (a) The eﬀect of FGS on the emergence of nuclear p65, indicative of NF-κB activation, was
determinedbyWesternBlotanalysis.RAW264.7cells,pretreatedwithvariousamountsofFGSfor16h(lanes2,3,5,6,8,and9),werefurther
treated with LPS (100ng/mL) for 15min and 30min (lanes from 4 to 9). The blot was stripped and reprobed against nuclear proteins lamin
A/C to ensure an equal loading. (b) RAW 264.7 cells, pretreated with 2.5, 5, or 10μg/mL of FGS for 24h, were treated with LPS (100ng/mL)
for16h,andtotalRNAwasextractedandanalyzedbysemiquantitativeRT-PCRforTNF-α.TheintensityofeachPCRproductwasmeasured
by densitometric analysis (ImageJ), and relative expression of TNF-α was calculated over GAPDH. (c) RAW 264.7 cells were treated similarly
to (b), and NO produced by the cells was measured. Data represent the mean ± SEM of three independent experiments.
[13, 17, 18]. To test this, we created an Nrf2 responsive
reporter cell line derived from RAW 264.7 cells. The cell line
harbors a 1kb long NQO-1 proximal promoter fused with
ﬁreﬂy luciferase gene. As shown in Figure 4(a),t r e a t m e n t
of the cell line with Sulforaphane, a well-documented Nrf2
activator, increased luciferase activity, suggesting the respon-
siveness of the reporter cell line to activated Nrf2 (columns
1 and 2). Treatment of the reporter cell line with FGS, 2.5
or 5μg/mL, for 16h induced luciferase activity (columns 4
and 5), demonstrating that FGS activates Nrf2. To determine
the eﬃcacy of FGS in activating Nrf2, we treated the reporter
c e l l sw i t hF G S( 2 . 5μg/mL) for various periods. As shown in
Figure 4(b), FGS treatment progressively increased luciferase
activity.
Next, we investigated whether the increased luciferase
activities by FGS treatment are correlated with nuclear
localization of Nrf2, indicative of activated Nrf2. After
similar treatments of RAW 264.7 cells with various amounts
of FGS, the nuclear proteins were extracted from the treated
cells and analyzed by western blotting for nuclear Nrf2. As
shown in Figure 4(c), Nrf2 was detected in the nucleus after
FGS treatment. To test whether FGS treatment also induces
Nrf2-regulatedgeneexpression,weperformedsimilarexper-
iment, extracted total RNA, and determined the expression
of NQO-1, GCLC, and HO-1 by semiquantitative RT-PCR
analysis. As shown in Figure 4(d), FGS treatment induced
the expression of Nrf2-regulated genes. Taken together, these
results show that FGS activated Nrf2, resulting in Nrf2-
dependent gene expression.
Finally, given that reactive oxygen species (ROS) exac-
erbates inﬂammation and activates Nrf2 [19], we sought to
exclude the possibility that FGS or other impurity, if any,
in FGS induces ROS production, resulting in Nrf2 activa-
tion. To this end, RAW 264.7 cells were treated with FGS
(25μg/mL), 10 times higher than the amount used in this
study, for 16h, and stained with carboxy-H2DCFDA prior to
ﬂow cytometric analysis. As shown in Figure 5, while LPS
treatment induced ROS production, FGS did not signiﬁ-
cantly elicit ROS production. In a similar experiment in
which the cells were treated with 5μg/mL of FGS, the level of
ROS was virtually same as that of control (data not shown).
Together, these results suggest that the anti-inﬂammatory
eﬀect of FGS is mediated, at least in part, by activating Nrf2
without mediation of ROS.Evidence-Based Complementary and Alternative Medicine 7
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Figure 4:FGSactivatesNrf2andinducestheexpressionofitsdependentgenes.AnNrf2reportercellline,derivedfromRAW264.7cells,was
treated with SFN (5μM) or the indicated amounts of FGS for 16h (a), or treated with 2.5μg/mL of FGS for various periods (b). Luciferase
activity was normalized by the amount of total proteins. Data represent the mean ± SEM of triplicate settings, and experiment was repeated
at least three times and shown are representatives (∗P<0.05 and ∗∗∗P<0.001, compared to control). (c) RAW 264.7 cells were treated
with FGS for 16h, and nuclear Nrf2 was measured by Western Blot analysis. (d) Expressions of Nrf2-dependent genes by FGS and internal
controls were determined by semiquantitative RT-PCR.
3.4. FGS Enhances the Expression of Nrf2-Dependent Genes
b u tS u p p r e s s e sT h a to fN F - κB-Dependent Genes in Inﬂamed
Mouse Lungs. To test whether the suppressive eﬀect of FGS
on lung inﬂammation is associated with Nrf2 activation, we
performed the similar experiment described in Figure 1,
and determined the expression levels of Nrf2- and NF-κB-
dependent genes in inﬂamed lungs. Mice (n = 5i ne a c h
experimental group) were fed with either ddH2Oo rt w o
diﬀerent doses of FGS (3.3 and 13.3mg/kg of a mouse) for
15 days prior to administration of intranasal LPS (10mg/kg
of a mouse) or sham. At 24h after the treatments, total RNA
extracted from the lungs was analyzed by semiquantitative
RT-PCR for the expression of Nrf2-dependnet (Figures 6(a)
and 6(b))a n dN F - κB-dependent genes (Figures 6(c) and
6(d)). As shown in Figure 6(a), FGS treatment induced the
expression of HO-1 expression (the 2nd column), which
is likely the result of ROS produced during inﬂamma-
tory reaction in the lung. FGS treatment induced HO-1
expression (the 3rd column), which was further increased in
inﬂamed lung (4th and 5th columns). Similar increases of
the expression of GCLC-1 were observed in inﬂamed lung
(3rd, 4th, and 5th columns in Figure 6(b)). On the other
hand, consistent with the results in Figure 1, LPS instillation
substantially induced the expression of proinﬂammatory
cytokinessuchasTNF-α(the2ndcolumninFigure 6(c))and
IL-1β (the 2nd column in Figure 6(c)), which were, however,
suppressedbyFGSinadose-dependentmanner(4thand5th
columns in Figures 6(c) and 6(d)). These results suggest that
FGS induces the expression of Nrf2-dependent genes and
suppresses that of NF-κB-dependent genes in the inﬂamed
lungs.
4. Discussion
Since A.D. 2 in China and eastern Asian countries, the
fruit hull of G. sinensis (FGS) has been prescribed for the8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: FGS does not signiﬁcantly generate intracellular ROS generation. RAW 264.7 cells were treated with LPS (100ng/mL) or FGS
(25μg/mL) for 16h, and ROSs were measured by ﬂow cytometric analysis. Experiment was repeated three times, showing no signiﬁcant
production of ROS by FGS compared to controls.
treatment of various respiratory symptoms such as cough,
wheezing, and other respiratory conditions with abscess
[20, 21]. However, it remains unknown how FGS exerts its
eﬀect. Given these recorded eﬀects of FGS on respiratory
diseases, we postulate and test whether FGS suppresses in-
ﬂammation by regulating key inﬂammatory transcription
factors. We demonstrated the suppressive eﬀect of FGS on
acute neutrophilic lung inﬂammation in ALI/ARDS in a
mouse model and provided evidence that FGS executes its
anti-inﬂammatory function via activation of an anti-inﬂam-
matory factor Nrf2. Our results suggest that the therapeutic
eﬀect of FGS is attributable to suppression of inﬂammation,
which is likely mediated by, at least in part, activating
Nrf2 but not suppressing proinﬂammatory factor NF-κB. To
our best knowledge, this is the ﬁrst experimental evidence
showing that FGS is eﬀective in regulating acute neutrophilic
lung inﬂammation and implicated in Nrf2 activation.
FGS is composed of numerous constituents including
tannins, resins, wax alcohols, beta-sitosterol, stigmasterol,
galactose, mannose, and saponins such as gledinin, gleditsia
saponins [20, 22–25]. Although our results suggested anti-
inﬂammatory eﬀect of FGS, it is also highly likely that some
of the constituents have other eﬀects. For example, as shown
in Figure 5, FGS treatment increased the size of the treated
cells compared to controls, as the size scattering became
diﬀused in FGS-treated cells. In addition, FGS treatment
alone increased the production of IL-1β in inﬂamed lung
(Figure 6(d)), although LPS induced, robust inﬂammation
in the lung was reduced by FGS. Nevertheless, our results
strongly suggest that the collective eﬀect of FGS was the
suppression of inﬂammation. A recent study reported that
FGS has a bacteriostatic eﬀect on Staphylococcus aureus,
Bacillussubtilis,andEscherichiacoli(E.coli)[26],theeﬀectof
which was attributed to gleditsia saponin [27]. Since one ofEvidence-Based Complementary and Alternative Medicine 9
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Figure 6:FGSenhancestheexpressionofNrf2-dependentgenesbutsuppressesthatofNF-κB-dependentgenesinmouselungs.Mice(n = 5
in each group), fed with either PBS or the indicated amounts of FGS, received an intranasal LPS (10mg/kg of a mouse) or sham. Expressions
of HO-1 (a), GCLC (b), TNF-α (c), and IL-1β (d) in the lungs were measured by semiquantitative RT-PCR. The intensity of each PCR band
was measured by densitometer and software (ImageJ), and relative expression of each gene was normalized against that of GAPDH. Data
represent the mean ± SEM. FGS induced the expression of HO-1 (a) and GCLC (b) in mouse lungs, and ∗∗∗P<0.001, compared to the
untreated control. LPS instillation to mouse lungs induced the expression of TNF-α (the 2nd column in (c)) and IL-1β (the 2nd column in
(d)), which were reduced by FGS (∗∗∗P<0.001, compared to LPS-treated control). FGS treatment alone induced the expression of IL-1β
(d); ∗P<0.05, compared to the untreated control).
the major causes of ALI/ARDS is septic infection by bacteria
and our results show that FGS suppressed LPS-induced neu-
trophilic lung inﬂammation, a key feature of ALI/ARDS, it is
likely that FGS is also eﬀective in treating ALI/ARDS caused
by Gram-negative bacterial sepsis.
NF-κB is a major transcription factor that governs the
expression of proinﬂammatory cytokines and chemokines
[28]. The roles of NF-κB in severe respiratory diseases such
as septic ALI and ARDS have been well documented, and
thusnumeroustherapeuticstrategiestocureALI/ARDShave
largely hinged on curbing NF-κB activity. However, those
strategies have shown no signiﬁcant clinical eﬀects [29, 30].
Rather, emerging evidence shows that Nrf2 plays a key role
in protecting from various respiratory diseases such as acute
lunginﬂammation,smoke-inducedemphysema,andasthma
[13, 17, 31, 32]. Nrf2, a member of the Cap’n’collar basic
region leucine zipper (CNC-bZIP) transcription factor fam-
ily, was originally known to activate cellular protective10 Evidence-Based Complementary and Alternative Medicine
pathways against oxidative injury [33]. Although ubiqui-
tously expressed, this nuclear factor is located abundantly
in tissues where detoxifying reactions routinely occur, such
as intestine, kidney, and lung [34]. Thus, regulation of Nrf2
can be an eﬀective therapeutic target in modulating inﬂam-
matory lung diseases.
Our results show that FGS had a suppressive eﬀect on
lunginﬂammationinanacutelunginjurymousemodel.RT-
PCR analyses of lung sections indicate that FGS enhanced
the expression of Nrf2 dependent genes but suppressed that
of NF-κB-dependent genes, suggesting that FGS suppresses
acute lung inﬂammation by both activating Nrf2 and sup-
pressing NF-κB. However, the data obtained from molecular
biologic analyses of macrophages suggest diﬀerently: FGS
only activates Nrf2 without interfering the activity of NF-
κB. Our study has a limitation in addressing Nrf2 activation
in a cell type speciﬁc manner, especially in the lung. Thus,
it is conceivable that FGS selectively suppressed the activity
of NF-κB in other parenchymal cells such as neutrophils in
the lung, but not in macrophages. Since Nrf2 activation in
macrophage cannot directly turn oﬀ the expression of NF-
κB-dependent genes in the same cell [35], it is unlikely that
Nrf2 activated by FGS in a particular parenchymal cell type
wasdirectlyinvolvedinsuppressingtheexpressionofNF-κB-
dependentgenesinthesamecelltypeinthelung.Rather,itis
possible that Nrf2 induced the expression of genes that could
null the proinﬂammatory responses in the context of the
inﬂammatory milieu. For instance, inﬂammatory response
involves reactive oxygen species (ROS) that exacerbate
inﬂammation [36]. At the same time, ROSs are a potent
activator of Nrf2 that enhances the expression of ROS scav-
engers such as NQO-1 and GCLC, resulting in reduced ex-
pression of proinﬂammatory cytokines such as TNF-α and
IL-1β. These possibilities warrant further studies. Neverthe-
less, our results suggest that FGS contains lead compounds
that are eﬀective in treating ALI/ARDS, suggesting that FGS
can be an option for the treatment of ALI/ARDS patients.
Oxidative stress culminated during inﬂammatory re-
sponses activates Nrf2 because macrophages and neutro-
phils, key eﬀectorcellsin regulating inﬂammatory responses,
produce ROS to remove pathogens. ROS, however, causes
damage to nearby cells, which in turn activates Nrf2 and
induces Nrf2-dependent gene expression in inﬂicted cells as
ap r o t e c t i v em e a s u r e[ 37]. Although an eﬀective arsenal for
removingpathogens,ROScancausecollateraltissuedamage.
Therefore,therapeuticsthatactivateNrf2withoutgenerating
ROS would be desirable to suppress inﬂammation without
unnecessary tissue damage. Our results show that FGS acti-
vatedNrf2withoutsigniﬁcantlygeneratingROSandinduced
Nrf2-dependent protective genes, suggesting that FGS can
mediateanti-inﬂammatoryfunctionswithnosignificantside
eﬀects.
5. Conclusions
Here, we provide, to our best knowledge, the ﬁrst experi-
mental evidence suggesting that FGS pretreatment protected
from acute neutrophilic lung inﬂammation, the hallmark of
ALR/ARDS, and that FGS activated an anti-inﬂammatory
factor Nrf2 without aﬀecting NF-κB activity. These results
suggest that the therapeutic eﬀect of FGS in traditional usage
for various respiratory diseases stems from suppression of
inﬂammation, which is associated with activation of anti-
inﬂammatory transcription factor. Our results also raise
the possibility that FGS can be used as an option for the
treatment of ALI/ARDS.
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